Blar i forfatter Artikler, rapporter og annet (farmasi) "Flatmark, Kjersti"

Viser treff 1-4 av 4

    • Ceramide-containing liposomes with doxorubicin: time and cell-dependent effect of C6 and C12 ceramide 

      Øverbye, Anders; Holsæter, Ann Mari; Fusser, Markus; Skalko-Basnet, Natasa; Iversen, Tore Geir; Torgersen, Maria Lyngaas; Sønstevold, Tonje; Engebråten, Olav; Flatmark, Kjersti; Mælandsmo, Gunhild; Skotland, Tore; Sandvig, Kirsten (Journal article; Tidsskriftartikkel; Peer reviewed, 2017-08-12)
      Doxorubicin, a widely used chemotherapeutic drug, has several potential high- risk side effects including cardiomyopathy. Furthermore, cellular resistance to this drug develops with time. By using liposomes as carrier vesicles both the side effects and drug resistance might be avoided. In this study we have investigated the cytotoxic effect of doxorubicin encapsulated in liposomes with and ...

    • Molecular signatures reflecting microenvironmental metabolism and chemotherapy-induced immunogenic cell death in colorectal liver metastases 

      Østrup, Olga; Dagenborg, Vegar Johansen; Rødland, Einar Andreas; Skarpeteig, Veronica; Silwal-Pandit, Laxmi; Grzyb, Krzysztof; Berstad, Audun Elnæs; Fretland, Åsmund Avdem; Mælandsmo, Gunhild; Børresen-Dale, Anne-Lise; Ree, Anne Hansen; Edwin, Bjørn; Nygaard, Vigdis; Flatmark, Kjersti (Journal article; Tidsskriftartikkel; Peer reviewed, 2017-07-18)
      Background: Metastatic colorectal cancer (CRC) is associated with highly variable clinical outcome and response to therapy. The recently identified consensus molecular subtypes (CMS1-4) have prognostic and therapeutic implications in primary CRC, but whether these subtypes are valid for metastatic disease is unclear. We performed multi-level analyses of resectable CRC liver metastases (CLM) to ...

    • Oncolytic peptides DTT-205 and DTT-304 induce complete regression and protective immune response in experimental murine colorectal cancer 

      Fleten, Karianne Giller; Eksteen, Johannes J.; Mauseth, Brynjar; Camilio, Ketil André; Vasskog, Terje; Sveinbjørnsson, Baldur; Rekdal, Øystein; Mælandsmo, Gunhild Mari; Flatmark, Kjersti (Journal article; Tidsskriftartikkel; Peer reviewed, 2021-03-24)
      Oncolytic peptides represent a novel, promising cancer treatment strategy with activity in a broad spectrum of cancer entities, including colorectal cancer (CRC). Cancer cells are killed by immunogenic cell death, causing long-lasting anticancer immune responses, a feature of particular interest in non-immunogenic CRC. Oncolytic peptides DTT-205 and DTT-304 were administered by intratumoral injection ...

    • Prognostic significance of S100A4 expression in stage II and III colorectal cancer: results from a population-based series and a randomized phase III study on adjuvant chemotherapy 

      Pedersen, Kjetil Boye; Jacob, Havjin; Frikstad, Kari-Anne; Nesland, Jahn M; Mælandsmo, Gunhild; Dahl, Olav; Nesbakken, Arild; Flatmark, Kjersti (Journal article; Tidsskriftartikkel; Peer reviewed, 2016-06-08)
      Current clinical algorithms are unable to precisely predict which colorectal cancer patients would benefit from adjuvant chemotherapy, and there is a need for novel biomarkers to improve the selection of patients. The metastasis-promoting protein S100A4 predicts poor outcome in colorectal cancer, but whether it could be used to guide clinical decision making remains to be resolved. S100A4 exp ...